Eli Lilly Reports Strong Q1 Results, Shares Rise on Beat-and-Raise
Eli Lilly reported a significant first-quarter revenue increase of 56% to $19.8 billion, surpassing analyst expectations, and raised full-year guidance. The stock surged 10% following the results, reversing earlier declines tied to healthcare sector rotation and competition in the GLP-1 market.
Topics: Earnings GLP-1 Market Pharmaceutical Industry Revenue Growth Stock Performance